Osteosarcoma is the most common primary malignant condition of the bone in children, adolescents, and young adults. We have reached a therapeutic plateau with standard chemotherapy. 1 RaCl 2 is a potentially lowtoxicity, high-efficacy targeted agent for osteosarcoma, which is an osteoblastic bone-forming tumor. 4 Knowing this, we hypothesized that 223 RaCl 2 could be safely administered to patients with osteosarcoma and that early response or resistance signals could be assessed by quantitative or qualitative correlative imaging studies. We designed a phase 1 clinical trial for patients with progressive, locally recurrent, or metastatic osteosarcoma with no standard curative options available with at least one indicator lesion avid on technetium Tc 99m-methylene diphosphate scan. The protocol was approved by the University of Texas MD Anderson Cancer Center institutional review board, and all participants provided written informed consent. The trial is ongoing and registered (NCT01833520).
Report of a Case | A man in his 20s with lung and brain metastatic osteosarcoma had been initially diagnosed with left femur osteosarcoma and had undergone standard osteosarcoma chemotherapy, surgery, and rotationplasty. A pathologic analysis showed less than 90% necrosis. He received preadjuvant and adjuvant high-dose methotrexate, cisplatin + doxorubicin, and ifosfamide + etoposide. While on surveillance, he developed sudden left hip pain and chest pain. Imaging revealed recurrence in the left ischium, a large calcific right lung mass, and cerebellar metastases. Biopsy confirmed osteosarcoma.
The patient was enrolled in the Discussion | This is the first clinical evidence of an alpha particle with blood-brain barrier (BBB) penetration and early evidence of 223 RaCl 2 activity in osteosarcoma. Interestingly, review of the literature revealed BBB penetration of a beta particle, Yttrium Y 90 ( 90 Y) ibritumomab tiuxetan, given intravenously to a patient with primary central nervous system lymphoma. 5, 6 After 90 Y ibritumomab tiuxetan administration, there was complete response in enhancing tumor where the BBB was leaky, but lesions occurred in other brain regions, where the BBB was intact. 6 Once a radionuclide is deposited in or near a cancer cell, the rate (half-life), range, and energy of radioactive particle emissions (MeV) are quite different within the target zone for alpha vs beta emitters. 1 The charged alpha particles from 223 Ra have far more mass and energy than beta particles (electrons). F, sodium fluoride 18; PET-CT, positron emission tomography-computed tomography; SUV max, maximum standardized uptake value; TF10, total Na 18 F activity in all malignant lesions with SUV of 10 or greater (an estimate of total metastatic burden); TLG, total lesional glycolysis. Letters
